Investigational agents for Crohn's disease.

Cottone M; Orlando A; M Renna S;

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful end point in clinical practice. WHAT THE READER WILL GAIN: We analyzed the main biological mechanisms of Crohn's disease and the new drugs whose use is based on insights into these mechanisms. We reviewed the following new drugs: probiotics, GM-CSF, IL-10, IL-11, anti-IL-6, anti-IL-12/-23, everolimus, anti-IFN-γ, IFN-β-I, co-stimulators, anti-integrins, anti-intercellular adhesion molecule 1, small molecules and mitogen-activated protein kinase inhibitors. TAKE HOME MESSAGE: Anti-TNF therapies remain the best options, followed by anti-integrin drugs. The most promising new therapies are anti-IL-23, but further data are necessary. The disappointing results with other molecules may depend on the quality of trials and possibly on inadequate dosage of the drug.
Lingua originaleEnglish
pagine (da-a)1147-1159
Numero di pagine12
RivistaExpert Opinion on Investigational Drugs
Volume19
Stato di pubblicazionePublished - 2010

Fingerprint

Crohn Disease
Interleukin-23
Pharmaceutical Preparations
Integrins
Interleukin-11
Biological Therapy
Probiotics
Intercellular Adhesion Molecule-1
Interleukin-12
Protein Kinase Inhibitors
Granulocyte-Macrophage Colony-Stimulating Factor
Mitogen-Activated Protein Kinases
Interleukin-10
Interleukin-6
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cita questo

Cottone M; Orlando A; M Renna S; (2010). Investigational agents for Crohn's disease. Expert Opinion on Investigational Drugs, 19, 1147-1159.

Investigational agents for Crohn's disease. / Cottone M; Orlando A; M Renna S;.

In: Expert Opinion on Investigational Drugs, Vol. 19, 2010, pag. 1147-1159.

Risultato della ricerca: Article

Cottone M; Orlando A; M Renna S; 2010, 'Investigational agents for Crohn's disease.', Expert Opinion on Investigational Drugs, vol. 19, pagg. 1147-1159.
Cottone M; Orlando A; M Renna S;. Investigational agents for Crohn's disease. Expert Opinion on Investigational Drugs. 2010;19:1147-1159.
Cottone M; Orlando A; M Renna S;. / Investigational agents for Crohn's disease. In: Expert Opinion on Investigational Drugs. 2010 ; Vol. 19. pagg. 1147-1159.
@article{3977daee0bbc4da2b02793c4adea7f7c,
title = "Investigational agents for Crohn's disease.",
abstract = "IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful end point in clinical practice. WHAT THE READER WILL GAIN: We analyzed the main biological mechanisms of Crohn's disease and the new drugs whose use is based on insights into these mechanisms. We reviewed the following new drugs: probiotics, GM-CSF, IL-10, IL-11, anti-IL-6, anti-IL-12/-23, everolimus, anti-IFN-γ, IFN-β-I, co-stimulators, anti-integrins, anti-intercellular adhesion molecule 1, small molecules and mitogen-activated protein kinase inhibitors. TAKE HOME MESSAGE: Anti-TNF therapies remain the best options, followed by anti-integrin drugs. The most promising new therapies are anti-IL-23, but further data are necessary. The disappointing results with other molecules may depend on the quality of trials and possibly on inadequate dosage of the drug.",
keywords = "biological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.",
author = "{Cottone M; Orlando A; M Renna S;} and Mario Cottone",
year = "2010",
language = "English",
volume = "19",
pages = "1147--1159",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Investigational agents for Crohn's disease.

AU - Cottone M; Orlando A; M Renna S;

AU - Cottone, Mario

PY - 2010

Y1 - 2010

N2 - IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful end point in clinical practice. WHAT THE READER WILL GAIN: We analyzed the main biological mechanisms of Crohn's disease and the new drugs whose use is based on insights into these mechanisms. We reviewed the following new drugs: probiotics, GM-CSF, IL-10, IL-11, anti-IL-6, anti-IL-12/-23, everolimus, anti-IFN-γ, IFN-β-I, co-stimulators, anti-integrins, anti-intercellular adhesion molecule 1, small molecules and mitogen-activated protein kinase inhibitors. TAKE HOME MESSAGE: Anti-TNF therapies remain the best options, followed by anti-integrin drugs. The most promising new therapies are anti-IL-23, but further data are necessary. The disappointing results with other molecules may depend on the quality of trials and possibly on inadequate dosage of the drug.

AB - IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful end point in clinical practice. WHAT THE READER WILL GAIN: We analyzed the main biological mechanisms of Crohn's disease and the new drugs whose use is based on insights into these mechanisms. We reviewed the following new drugs: probiotics, GM-CSF, IL-10, IL-11, anti-IL-6, anti-IL-12/-23, everolimus, anti-IFN-γ, IFN-β-I, co-stimulators, anti-integrins, anti-intercellular adhesion molecule 1, small molecules and mitogen-activated protein kinase inhibitors. TAKE HOME MESSAGE: Anti-TNF therapies remain the best options, followed by anti-integrin drugs. The most promising new therapies are anti-IL-23, but further data are necessary. The disappointing results with other molecules may depend on the quality of trials and possibly on inadequate dosage of the drug.

KW - biological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.

UR - http://hdl.handle.net/10447/52953

M3 - Article

VL - 19

SP - 1147

EP - 1159

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

ER -